Virpax Pharmaceuticals Inc（VRPX）股票分析

$0.670

-0.302 (-45.12%)收盤時

Loading chart…

High: 1.180
Open: 1.180
VWAP: 0.77
Vol: 2.78M
Mkt Cap: 1.43M
Low: 0.450
Amount: 2.13M
EV/EBITDA, TTM: 0.00

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain.

virpaxpharma.com

估值指標

The current forward P/E ratio for Virpax Pharmaceuticals Inc (VRPX) is -0.21, compared to its 5-year average forward P/E of -0.63.

Forward P/E

Overvalued

5Y Average P/E

-0.63

Current P/E

-0.21

高估

-0.26

低估

-1.01

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

高估

0.00

低估

0.00

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

高估

0.00

低估

0.00

事件時間軸

2025-03-19 (ET)

08:11:16

Virpax Pharmaceuticals announces 1-for-25 reverse stock split

2025-03-18 (ET)

16:02:21

Virpax receives positive Probudur results for dose range study

2025-02-27 (ET)

16:16:09

Virpax Pharmaceuticals reports Molecular Envelope Technology human study data

2025-02-13 (ET)

15:03:21

Virpax Pharmaceuticals confirms results with U.S. Army with Probudur

2024-11-22 (ET)

07:34:02

Virpax Pharmaceuticals announces results from Probudur minipig DRF study

Show More Events

資訊

VRPX FAQ — answered by Alphio AI

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。